Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study

PURPOSE: In the phase III CLARINET study (NCT00353496), lanreotide autogel/depot (lanreotide) significantly improved progression-free survival (PFS) vs placebo in patients with non-functioning intestinal or pancreatic neuroendocrine tumours (NETs). The aim of CLARINET open-label extension (OLE) (NCT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocrine
Main Authors: Caplin, Martyn E., Pavel, Marianne, Phan, Alexandria T., Ćwikła, Jarosław B., Sedláčková, Eva, Thanh, Xuan-Mai Truong, Wolin, Edward M., Ruszniewski, Philippe
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7881960/
https://ncbi.nlm.nih.gov/pubmed/33052555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-020-02475-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados